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Abstract
Background: Primordial Odontogenic Tumor (POT) is a recently described odontogenic tumor characterized by a 
variably cellular loose fibrous tissue with areas similar to the dental papilla, covered by cuboidal to columnar epi-
thelium that resembles the internal epithelium of the enamel organ, surrounded at least partly by a delicate fibrous 
capsule. The purpose of this study was to investigate the possible histogenesis and biological behavior of this rare 
tumor by means of a wide immunohistochemical analysis of its epithelial and mesenchymal components.
Material and Methods: The immunoexpression of twenty-three different antibodies were evaluated in four cases 
of POT.
Results: The epithelial cells that cover the periphery of the tumor showed immunopositivity for Cytokeratins 14 
and 19, while Amelogenin, Glut-1, MOC-31, Caveolin-1. Galectin-3, PITX2, p53, Bax, Bcl-2, Survivin and PTEN 
were variably expressed in focal areas. The mesenchymal component of the tumor was positive for Vimentin, Syn-
decan-1, PITX2, Endoglin (CD105), CD 34, Cyclin D1, Bax, Bcl-2, Survivin and p53. PTEN and CD 90 showed a 
moderate positivity.  BRAF V600E and Calretinin were negative in all samples. Cell proliferation markers (Ki-67, 
MCM-7) were expressed in <5% of the tumor cells.
Conclusions: According to these immunohistochemical findings, we may conclude that POT is a benign odonto-
genic tumor in which there is both epithelial and mesenchymal activity during its histogenesis, as there is expres-
sion of certain components in particular zones in both tissues that suggests this tumor develops during the imma-
ture (primordial) stage of tooth development, leading to its inclusion within the group of benign mixed epithelial 
and mesenchymal odontogenic tumours in the current World Health Organization classification of these lesions.
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Introduction
Odontogenic tumors derive from the tooth-producing 
tissues or its remnants, which are entrapped either with-
in the jawbones or in the adjacent soft tissues. Biologi-
cally, some of these lesions are hamartomas that show 
varying degrees of differentiation, while the others com-
prise both benign and malignant neoplasms exhibiting 
variable aggressiveness and potential for metastasis (1).
In 2014, our group reported for the first time an odon-
togenic tumor characterized by a variably cellular loose 
fibrous tissue with areas similar to the dental papilla, 
entirely surrounded by cuboidal to columnar epitheli-
um that resembles the internal epithelium of the enamel 
organ and covered at least partly by a delicate fibrous 
capsule. The fact that the epithelium is located periph-
erally recalls the relationship between the immature in-
ner enamel epithelium and the primitive dental papilla 
at a time when no inductive ecto-mesenchymal effects 
have occurred, and then it mimics the primordial stages 
of tooth development, apparently lacking the ability to 
follow a normal inductive evolution to produce the sub-
sequent stages histo and morpho-differentiation of the 
dental tissues. This is the reason why we proposed the 
name “Primordial Odontogenic Tumor” (POT) as a de-
scriptive term for this entity (2).
To date, seven cases of POT have been reported in the 
literature, all of which were found as well-defined radi-
olucent lesions adjacent to the crown of an unerupted 
tooth, producing varying degrees of bone expansion, 
root resorption and displacement of adjacent teeth, and 
macroscopically appeared as whitish solid tumors that 
tended to be encapsulated or at least well-defined from 
the surrounding structures (2,3).  
The aim of this study was to better characterize POT 
both histopathologically and immunohistochemically, 
through the use of a large panel of antibodies. A fur-
ther objective was to discuss the possible implications 
or functions held by each of the analyzed proteins in 
order to elucidate the possible histogenesis and biologi-
cal behavior of this rare tumor.
Material and Methods
Four cases of POT retrieved from three different Centers 
of Oral Pathology in Latin America (Two from Mexico, 
one from Brazil and one from Guatemala) were includ-
ed in the present study. All of them belong to the series 
of six cases originally published by our group in 2014 
(2). New immunohistochemical studies were performed 
with a panel of 23 different antibodies.
Paraffin blocks were cut and three-μm sections were 
set on glass slides previously treated with poly-lysine; 
we then proceeded to deparaffinize and rehydrate the 
slides and to perform antigen retrieval through treat-
ment with 0.1 M sodium citrate (pH 6.2) and Tween 
20 in microwave to unmask the epitopes. Endogenous 
peroxidases were blocked with 0.9% hydrogen perox-
ide. Primary antibodies for Amelogenin, CK19, CK 
14,Vimentin, Calretinin, Syndecan-1, Glut-1, Galec-
tin-3, Ki-67, MCM-7, Cyclin D1, PTEN, p-53, PITX2, 
Caveolin-1, BRAFV600E, Epithelial Related Antigen 
(MOC-31), CD-34, Endoglin (CD105), CD-90, Bax, 
Bcl-2 and Survivin were incubated for 45 min (Table 1). 
Afterwards the slides were incubated with a biotinylat-
ed anti-mouse/anti-rabbit antibody and the streptavidin/
peroxidase complex for 30 minutes each (LSAB þ-la-
beled streptavidin-biotin, Dako). To visualize the reac-
tion a 3,30-diaminobenzidine-H2O (Dako) substrate 
was used. Finally, the sections were counterstained with 
Mayer’s hematoxylin solution. For the negative controls, 
the primary antibody was replaced with PBS.
For the cytoplasmic and/or membranous positivity the 
quantification was performed visually using an opti-
cal microscope (Eclipse Ci-L, Nikon, Japan) within 10 
high-power fields/slide at the 40X objective amplifica-
tion according to the following semi-quantitative scale. 
A score of 0 (“essentially no staining”) was established 
for negative or positive immunohistochemical staining 
of < 5% of the cells; + (“weak-moderate”) for stain-
ing of 5 to 50% of cells, and ++ (“strong positive”) for 
>50% positive staining. When the positivity was in the 
nucleus, the cell counts were performed as previously 
described by Bologna-Molina R, et al. (4). The labeling 
index (number of positive tumor cells/total number of 
tumor cells expressed as a percentage) was calculated 
in every case. The cell count was performed both in the 
mesenchymal component of the tumor and on the epi-
thelial component surrounding each lesion. Two differ-
ent oral pathologists assessed the immunohistochemical 
expression individually before reaching a consensus. 
The standardization of the examiners showed a kappa 
index of 0.90.
Results
The clinical data of the four cases, including sex, age, 
location, clinical and radiographic findings, treatment 
and follow-up were described in our previous work (2) 
and are summarized in table 2. 
The immunohistochemical findings show that the mes-
enchymal component of the tumor was positive in the 
fusocellular cells for Vimentin, Syndecan-1, PITX2, 
Bax, Bcl-2, Survivin and p53. Syndecan-1 positivity 
was also observed in the extracellular matrix. CD-34 
and CD-105 (Endoglin) were variably positive in blood 
vessels, while PTEN and CD 90 showed weak-moderate 
positivity (see Table 1 and Figs. 1-3). The epithelial cells 
that surround the periphery of the tumor were positive 
for CK 14 and in most areas also for CK19, Amelogenin, 
Glut-1, Epithelial Related Antigen (MOC-31) and Cave-
olin-1. Galectin-3, PITX2, p53, Bax, Bcl-2, Survivin 
and PTEN were variably expressed. On the other hand, 
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Antibody Source/clone Dilution Epithelial 
cells 
Mesenchymal 
cells 
Amelogenin Santa Cruz/F-11 1ௗ:ௗ100 + Neg 
CK19 Genetex/polyclonal 1ௗ:ௗ100 ++ Neg 
CK 14  Biocare/LL002 1:100 ++ Neg 
Vimentin DAKO/V 9 1:100 + ++ 
Calretinin DAKO/DAK-CALERET 
1 
1ௗ:ௗ100 Neg Neg 
Syndecan-1 (CD138) DAKO/MI15 1ௗ:ௗ100 Neg ++ 
Glut-1 GeneTex/E107 1ௗ:ௗ100 ++ Neg 
Galectin-3 Bio SB/9C4 1:50 + Neg 
Ki-67 DAKO/MIB1 1ௗ:ௗ100 <2% <5% 
MCM-7 Leica/ DCS-141.1 1:100 <1% <1% 
Cyclin D1 DAKO/DCS-6 1:50 <5 %. <5 %. 
p-53 Bio SB/D07 1:200 + + 
PITX2 Abcam/ab32832 1:50 + + 
Caveolin-1 Santa Cruz/polyclonal 1:100 + Neg 
BRAFV600E Bio SB/RM8 1:100 Neg Neg 
Epithelial Related Antigen (MOC-31) DAKO/MOC-31 1:50 + Neg 
CD-34 Biocare/QBEnd10 1:100 Neg ++ (Vessels) 
Endoglin (CD105) DAKO/SN6h 1:100 Neg +(Vessels) 
Bcl-2 Biocare/100/D5 1:100 + + 
Bax GeneTex/polyclonal 1:200 + + 
Survivin GeneTex/polyclonal 1:200 + + 
CD90 STEMCELL/5E10 1:100 Neg + 
PTEN Santa Cruz 1:100 + Neg 

Table 1: Immunoexpression of the 23 studied antigens in the epithelial and mesenchymal cells of POT samples.
Neg: negative, +: weak-moderate, ++: strong positive.
BRAF V600E and Calretinin were negative in both the 
mesenchyme and the epithelium.
Discussion
This study widely describes the immunohistochemi-
cal profile of POT. The selected markers provide new 
and valuable information for a better understanding 
of the possible histogenesis and biological behavior of 
this entity. Previous studies have demonstrated that im-
munoexpression patterns of CKs during odontogenesis 
vary with respect to specific cell types, as well as to 
the diverse developmental stages and the degree of dif-
ferentiation of the epithelium (5). Although several CKs 
are expressed in the epithelial cells of the tooth germ 
(6), CK 14 is the one that seems to be present constantly 
in all stages of tooth development and in most neoplastic 
epithelial cells in odontogenic tumors (7-9), in contrast 
to CK 19, which increases its expression once the inner 
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epithelial cells become potential ameloblasts (8). On the 
other hand, immunostaining of amelogenin in young or 
immature enamel matrix areas occurs in around 95% of 
the enamel protein. This protein, which is synthesized 
in young ameloblasts, is secreted into enamel matrix 
(10) and is gradually almost entirely removed by degra-
dation by extracellular enzymes during enamel matura-
tion (11). The presence of CK 19 and CK14 as well as 
the observed immunopositivity for Amelogenin in the 
epithelium of our cases of POT is a supporting evidence 
of an odontogenic origin of this tumor (Figs. 1a-c). It is 
interesting to note that both Amelogenin and CK 19 did 
not exhibit a uniform expression in all epithelial cells, 
as these predominated in the cubic and columnar cells 
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Fig. 1: (a) The epithelium showS variable expression of CK19, 
400X. (b) Expression of CK 14 was constant throughout the 
epithelium, 200X. (c) Expression of Amelogenin in the cubic 
and columnar cells, 200X. (d) Syndecan-1 is intensely ex-
pressed in the mesenchyme, but not in all the epithelial lin-
ing, 200X. (e) PITX2 positivity in focal areas, 400X. (f) Ex-
pression of GLUT-1 in the odontogenic epithelium, 200X. (g) 
MOC-31 was only found expressed in localized areas within 
the epithelium, 200X. (h) Some epithelial cells showed posi-
tivity for vimentin, 400X.
Fig. 2: (a) Expression of Ki-67 in epithelial cells; 400x, (b) 
significantly higher proliferative index within the cells in the 
subepithelial mesenchymal condensation (arrow) as com-
pared to that found in other mesenchymal areas of the tumor; 
200X. (c) Expression of Galectin-3 in epithelial cells; 100X. 
(d,e,f) Bax, Bcl-2 and Survivin expression; 400X.  (g) p53 
was found both in the mesenchymal component and in the 
surrounding epithelium; 400X. (h) Cyclin D1 expression; 
400X.
showing inverse polarization (pre-ameloblasts), which 
suggests that this epithelial lining express diverse de-
grees of maturation, supporting an origin from primi-
tive (primordial) cellular components of the enamel or-
gan (Figs. 1a-c). This observation is also reinforced by 
the fact that some areas of the tumor epithelium showed 
focal positivity to vimentin (Fig. 1h).
MOC-31 is an epithelial-related antigen expressed in 
most normal epithelia but also in tumors originating 
from epithelial tissues. This is a cell adhesion molecule 
that allows tight junction formation between epithe-
lial cells, which can negatively affect cadherin/catenin 
complex formation (12). MOC-31 has been proved to be 
an advantageous marker at signaling epithelial cell dif-
ferentiation. Reduced expression of MOC-31 has been 
correlated with poor survival in cancerous conditions. 
It could be related to differentiation, tumor proliferation 
and invasion (13,14). This molecule was found only ex-
pressed in localized areas within the epithelium of the 
studied POT cases (Fig. 1g), suggesting, as seen for CK 
19, Vimentin and Amelogenin, that there is a variable 
degree of differentiation and maturation of the cells that 
comprises the epithelial compartment. 
As a member of the family of transmembrane heparan 
sulfate proteoglycans, Syndecan-1 (CD138) is involved 
in cell to cell adhesion and in the interaction of cells 
with the extracellular matrix, and also participates 
in promoting cell proliferation and regulates cellular 
growth by interacting with families of growth factors in 
association with heparin (15). Syndecan-1 plays a role 
in epithelial maturation, and it has been consistently 
observed that the degree of epithelial differentiation is 
directly associated with its expression (16). In addition, 
it has been reported that the pattern of Syndecan-1 ex-
pression varies according to the stage of maturation of 
the epithelial tissues (17). In this respect, it is relevant 
to highlight the fact that in all cases of POT included in 
this study, there were different degrees of Syndecan-1 
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Fig. 3: (a) Strong CD34 positivity in mesenchymal cells located in contact or closer to 
the odontogenic epithelium and in blood vessels; 200X. (b) CD 105 mainly expressed 
in blood vessels located in the areas of greater condensation of mesenchymal cells, par-
ticularly in the subepithelial region, thus signaling neoangiogenesis activity in this tu-
moral area; 200X. (c) Expression of CAV-1 in odontogenic epithelium; 400X (d) Slight 
expression of PTEN in focal areas of the epithelium; 400X.
expression in the tumoral epithelium, ranging from en-
tirely negative areas to focally positive zones (Fig. 1d). 
This suggests that there are groups of epithelial cells 
with different degrees of maturation within the epithe-
lial compartment of this tumor, which coincides with 
the differences in expression observed with MOC-31, 
CK19 and amelogenin. On the other hand, it was also 
noted a strong stromal expression of Syndecan-1 in ar-
eas of mesenchymal condensation (papilla-like tissue), 
particularly in the subepithelial regions (Fig. 1d). Vaino 
et al.  reported that Syndecan RNA accumulates in the 
condensing mesenchymal cells around the invaginating 
epithelial tooth bud during early development, and this 
accumulation is more intense when morphogenesis ad-
vances towards the cap stage, and also that Syndecan 
expression is lost during the bell stage (18). The same 
group found that Syndecan-1 was intensely expressed in 
the mesenchyme, but not in the epithelium, by prolifer-
ating cells during the process of odontogenesis, suggest-
ing a possible interaction of these tissues with growth 
factors (Fig. 1d) (19). These facts led us to consider that 
this lesion mimics the early (primordial) stages of tooth 
development.
PITX2 is selectively expressed in the early stages of 
morphogenesis in oral ectoderm and epithelial cells. 
Fine-tuned molecular signaling between the oral epithe-
lium and the ectomesenchyme is involved in tooth de-
velopment and it is considered a marker for the initiation 
of dental development (20,21). In vitro studies in human 
and mouse cells have shown that a mesenchymal signal 
is required to maintain PITX2 expression in the epithe-
lium throughout tooth development (22). In the present 
study we found weak immunostaining for PITX2 in the 
fusiform mesenchymal cells in the four cases of POT, 
whereas the endothelial cells presented weak to mod-
erate positivity (Fig. 1e). On the other hand, epithelial 
cells showed moderate positivity in focal areas (Figure 
1e). According to Mucchielli et al. (22), PITX2 expres-
sion occurs in the area of the presumptive dental lamina, 
remaining as a marker for dental epithelium throughout 
morphogenesis until it is downregulated in differenti-
ated ameloblasts. The presence of this transcription fac-
tor, at least focally in the tumoral epithelium, also lend 
support to the hypothesis that this tumor derives from 
the early stages of dental morphogenesis and that the 
epithelial components express different stages of tooth 
development.
In mammalian cells, glucose is fundamental for metabo-
lism. A family of transporters, called glucose transport-
ers or Gluts, mediates its passage across cell membranes. 
Glucose Transporter Glut-1 is found in normal cells, 
such as erythrocytes and endothelium at the blood-brain 
barrier in perineural cells, and in the basal layer of oral 
epithelium and epidermis. Conditions in which the met-
abolic rate must be adjusted can induce increased glu-
cose transport via Glut-1. Examples of such conditions 
are cell division, differentiation, nutrient starvation and 
hypoxia, which are frequently found in embryological 
tissues and in those with malignant transformation (23). 
Glut-1 is also expressed in odontogenic tumors, and it 
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has been observed increased in ameloblastomas and 
ameloblastic carcinomas as compared to tooth germs, 
which suggests its overexpression may play an impor-
tant role in the aggressive behavior of these neoplasms 
(24). In the present study we found a strong expression 
of this glucose transporter in odontogenic epithelium, 
showing both cytoplasmic and membranal localization 
(Figure 1f), which correlates well with the fact that the 
pattern of Glut-1 expression changes from strong cyto-
plasmic expression to membranous expression during 
maturation of the enamel organ in the late bell stage 
(24). The strong expression of this protein in the epi-
thelium of POT indicates the existence of high glucose 
transport requirements in this pathological condition. 
On the other hand, the cytoplasmic and membranous 
expression also suggests the co-existence of different 
stages of maturation in this epithelium.  
In order to quantify the proliferative activity of the tu-
mor we used markers associated to cell proliferation and 
factors related to cell –cycles, such as Ki-67, MCM7 
and Cyclin D1, which revealed that the tumor presents 
a low rate of proliferation (< 5%) in both epithelial and 
mesenchymal cells (Fig. 2a,b), similar to that reported 
for other benign odontogenic tumors, such as the odon-
togenic myxoma (25). Additionally, it is important to 
highlight the fact that there was a significantly higher 
proliferative index among the cells located within the 
subepithelial mesenchymal condensation as compared 
to that found in other mesenchymal areas of the tumor 
(Fig. 2b). This may imply that the tumor shows more 
active growth in this specific area, and perhaps it may 
be related to the inductive ability of that part of the mes-
enchyme to modify the overlying epithelium. 
Galectin-3, a lectin involved in diverse biological events 
including embryogenesis, cell adhesion, proliferation, 
apoptosis, mRNA splicing and regulation of the im-
mune system (26), is widely present in human tissues. 
Changes in Galectin-3 expression and its subcellular 
and intercellular localization are commonly observed 
in cancer and precancerous conditions (27). While a 
general shift of galectin-3 localization from nucleus to 
cytoplasm occurs in cancer development from adeno-
ma to carcinoma and also this protein plays an impor-
tant pivotal role within the nucleus in the regulation of 
cancer-related gene expression (27), including Cyclin 
D1, its expression in POT in this study was exclusively 
found in the epithelial component, mainly in the cyto-
plasm (yet some cells showed immunopositivity in the 
nucleus) (Figs. 2c,h), suggesting a possible role in cell 
proliferation. As occurred with other immunomarkers, 
there were areas in the epithelium that were completely 
negative and some which showed clear expression (Fig. 
2c). Nakahara et al. (28) have suggested that overex-
pression of intracellular galectin-3 favors neoplastic 
transformation, cell cycle progression and inhibition of 
apoptosis, but the exact significance of our findings re-
mains to be elucidated. 
The range of survival or cellular death is determined 
by the relationship between Bcl-2 (an apoptosis inhibi-
tor) and Bax (an apoptosis promoter). In addition, Sur-
vivin is an antiapoptotic protein that leads to negative 
regulation of apoptosis by inhibiting caspase activation 
(29). When Bax predominates over Bcl-2, the activity 
of Bcl-2 is repressed and the apoptotic pathway of Bax 
is activated (30). In this study Bcl-2, Survivin and Bax 
manifested strong positivity in both mesenchymal and 
epithelial cells of POT (Figs. 2d,e,f). The expression 
of Bax, Survivin and Bcl-2 was similar, with slightly 
greater presence of the antiapoptotic proteins; however, 
the results of this study does not allow us to conclude 
that the overexpression of antiapoptotic proteins play an 
important role as growth mechanism of POT, as it has 
been suggested for other odontogenic neoplasms (31). It 
is interesting to note that nuclear immunoexpression of 
Survivin was detected in some areas of the epithelium 
(Fig. 2f), which according to Stasikowska-Kanicka et 
al. (32), fosters cell proliferation, while its cytoplasmic 
immunoexpression is involved in the mechanisms of 
apoptosis regulation. On the other hand, both Bcl-2 and 
Bax participate as transcriptional targets for p53, a tu-
mor suppressor protein, which brings about cell cycle 
arrest or apoptosis in response to DNA damage. The 
coordinate activity of these molecules is vital in order to 
control life and death of a cell (33). A weak to moderate 
expression of p53 was found both in the mesenchymal 
component and in the surrounding epithelium in our 
cases (Fig. 2g), which is evidence that this protein par-
ticipates as part of the regulation of this tissue.
Blood supply is required for tumor growth, to provide 
the oxygen, metabolites and growth factors necessary 
for cell proliferation. Blood vessels feeding the tu-
mor were identified by means of CD34 and Endoglin 
(CD-105) expression, demonstrating strong positivity 
for CD34 in all the endothelial cells, whereas CD 105 
marked a smaller number of blood vessels (Figs. 3a,b). 
This situation may be explained by the fact that CD-105 
expression, contrary to CD34, is a characteristic prop-
erty of newly formed blood vessels and not of previous-
ly-existing blood and lymphatic vessels (34). CD 105 
in POT was found mainly in blood vessels located in 
the areas of greater condensation of mesenchymal cells, 
particularly in the subepithelial region, thus signaling 
neoangiogenesis activity in this tumoral area (Fig. 3b), 
which agrees with our previous suggestion that the tu-
mor has a greater growth rate in this area. In this recently 
recognized tumoral entity we found that CD34 showed 
immunopositive areas not only in the mesenchymal ves-
sels, but also in the mesenchymal cells located in con-
tact or closer to the odontogenic epithelium (Fig. 3a). 
CD34 is known to be a marker for hematopoietic stem 
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cells, and hematopoietic progenitor cells (35), but also it 
is regarded as a marker of several other nonhematopoi-
etic cell types, including vascular endothelial progeni-
tors and embryonic fibroblasts (36,37), and therefore we 
consider that its positivity in this area could indicate the 
presence of embryonic fibroblasts (38,39).
CD90 has been established as a marker for a wide vari-
ety of human cell-stem types, and particularly mesen-
chymal stem cells. It is considered to be a vital regulator, 
critical at cell-cell and cell-matrix interactions. It takes 
part in cellular migration and fibrosis, both of which are 
important events for tissue regeneration and oncogen-
esis (40). Its expression in tumor stroma, especially in 
endothelial and mesenchymal stem cells, including tu-
mor-associated fibroblasts, appears to be an influential 
agent in disease progression (41). Stromal expression 
of CD90 in our POT cases was found in blood vessels 
and in some mesenchymal cells, particularly in those in 
close proximity to epithelial odontogenic cells, which 
led us to suggest that CD90 expression in POT could 
play an important role in cellular adhesion and migra-
tion, serving as an important regulator of cell-matrix 
interactions for determining the biological behavior of 
this tumor. 
Expression of Caveolin-1 (Cav-1) was reported by Schwab 
et al. (42) in epithelial and mesenchymal cells of tooth 
germ in various stages of development, particularly in 
the inner enamel epithelium and ameloblastic cells in de-
veloping tooth germ (42), and it has also been established 
that Cav-1 participates in oncogenic transformation and 
differentiation in oral squamous cell carcinoma and pros-
tate cancer (43,44). Regarding its tumor promoting func-
tion, higher expression of Cav-1 drives into tumorgenesis 
by inhibiting apoptosis (44). The variable expression that 
we found within the epithelial component of POT (Fig. 
3c) could suggest different stages of cellular differen-
tiation within the odontogenic epithelium covering the 
lesion, implying that positive cells are the transformed 
cells of this particular type of tumor.
PTEN gene, which in humans encodes the protein phos-
phatase and tensin homolog, (PTEN), was identified as a 
tumor suppressor gene that mutates with a high frequen-
cy in a large number of cancerous condition. Reduced 
expression of PTEN has also been reported in some oral 
cancers, in studies that suggest PTEN plays an important 
role at signaling pathways in the carcinogenesis of head 
and neck squamous cell carcinoma (45). In our study, we 
observed only a slight expression of PTEN in focal areas 
of the epithelium (Fig. 3d), reinforcing the hypothesis of 
the existence of cells with different stages of develop-
ment within the epithelial compartment. 
Recently, dysregulation of the MAPK pathway signal-
ing have been proved as a critical step in the pathogen-
esis of ameloblastoma. The mutation most frequently 
identified is BRAF V600E. (46). To date, BRAF V600E 
mutations have been identified also in ameloblastic fi-
bromas (2/2) and fibrodentinomas (1/1), as well as in 
ameloblastic carcinomas (3/8) and clear cell odontogen-
ic carcinomas (1/1), but not in other odontogenic tumors 
(47,48).  In our POT cases, we did not find the presence 
of the mutant protein BRAFV600E, and the absence of 
this mutation positions POT in a different category with 
respect to the ameloblastic lesions.
According to the variable extent of expression of the 
diverse proteins tested in this study, we may conclude 
that POT has a low proliferative index, which defines it 
as a slowly growing lesion with variable production of 
loose fibrous tissue in which cell proliferation does not 
seem to be the only growth mechanism implicated in 
its expansion. POT is a moderately vascularized tumor, 
in which there is greater vascular density and vascular 
neoformation in the mesenchyme located just below the 
epithelium, an area that also shows greater expression 
of Syndecan 1, CD 34, Ki-67 and Glut-1, indicating that 
this is the area with the greatest proliferative activity 
and in which the necessary elements for the develop-
ment of the tumor converge. In addition, there is some 
evidence of an increase of antiapoptotic activity that 
may participate in the growth of this tumoral entity. The 
uneven expression of CK19, Vimentin, Amelogenin, 
Syndecan-1, CAV 1, Glut-1 1, MOC-31 and PITX2 in 
the surrounding epithelium could be interpreted as that 
there are groups of cells in different stages of develop-
ment within an apparently unique epithelial structure. 
This situation leads us to speculate that the epithelial 
compartment of POT is not a uniform or static structure 
in odontogenesis, but that it expresses the transition be-
tween the earliest stages of tooth development and those 
in which ameloblastic maturation is present, but before 
having the potential for induction of odontoblastic dif-
ferentiation or the production of mineralized tissues, 
supporting the denomination of “primordial” for this 
unique entity. The absence of identifiable BRAF V600E 
mutant protein suggest that mutation of BRAF gene 
is not implicated in the pathogenesis of POT, and may 
confirm that this tumor does not belong to the category 
of those BRAF-mutant positive ameloblastic tumors.
Considering and putting together all these immunohis-
tochemical findings, we interpret that the lesion studied 
is an odontogenic tumor of benign behavior that pos-
sibly originates from the mesenchyme of an abortive 
tooth germ that fails to produce a dental organ. Given 
the rarity of this tumor and the small number of cases 
reported to date, it is necessary to collect new cases in 
order to obtain a larger sample, towards a better under-
standing of the histogenesis and tumoral behavior of 
this condition.
References 
1. Mosqueda-Taylor A. New findings and controversies in odon-
togenic tumors. Med Oral Patol Oral Cir Bucal. 2008;13:555-8.
Med Oral Patol Oral Cir Bucal. 2017 May 1;22 (3):e314-23.                                                                                                                                                                    Primordial odontogenic tumor
e322
2. Mosqueda-Taylor A, Pires FR, Aguirre-Urízar JM, Carlos-Breg-
ni R, de la Piedra-Garza JM, Martínez-Conde R, et al. Primordial 
odontogenic tumour: clinicopathological analysis of six cases of a 
previously undescribed entity. Histopathology. 2014;65:606-12.
3. Slater LJ, Eftimie LF, Herford AS. Primordial Odontogenic Tu-
mor: Report of a Case. J Oral Maxillofac Surg. 2016;74:547-51.
4. Bologna-Molina R, Damián-Matsumura P, Molina-Frechero 
N. An easy cell counting method for immunohistochemistry 
that does not use an image analysis program. Histopathology. 
2011;59:801-3.
5. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The cata-
log of human cytokeratins: patterns of expression in normal epithe-
lia, tumors and cultured cells. Cell. 1982;31:11-24.
6. Pelissier A, Ouhayoun JP, Sawaf MH, Forest N. Evolution of cy-
tokeratin expression in developing human tooth germ. J Biolog Buc-
cale. 1990;18:99-108.
7. Heikinheimo K, Hormia M, Stenman G, Virtanen I, Happonen RP. 
Patterns of expression of intermediate filaments in ameloblastoma 
and human fetal tooth germ. J Oral Pathol Med. 1989;18:264-73.
8. Crivelini MM, de Araújo VC, de Sousa SOM, de Araújo NS. Cytok-
eratins in epithelia of odontogenic neoplasms. Oral Dis. 2003;9:1-6.
9. Kumamoto H, Yoshida M, Ooya K. Immunohistochemical detec-
tion of amelogenin and cytokeratin 19 in epithelial odontogenic tu-
mors. Oral Dis. 2001;7:171-6.
10. Mori M, Yamada K, Kasai T, Yamada T, Shimokawa H, Sasaki 
S. Immunohistochemical expression of amelogenins in odontogenic 
epithelial tumours and cysts. Virchows Arch. 1991;418:319-25.
11. Zalzal SF, Smith CE, Nanci A. Ameloblastin and amelogenin 
share a common secretory pathway and are co-secreted during 
enamel formation. Matrix Biol. 2008;27:352-9.
12. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de 
Bruijn IH, Prins F, et al. Epithelial cell adhesion molecule (ep-cam) 
modulates cell-cell interactions mediated by classic cadherins. J Cell 
Biol. 1997;139:1337-48.
13. Ordóñez NG. Value of the MOC-31 monoclonal antibody in dif-
ferentiating epithelial pleural mesothelioma from lung adenocarci-
noma. Hum Pathol. 1998;29:166-9.
14. Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, 
Mulligan LM, et. al. Reduction in membranous immunohistochemi-
cal staining for the intracellular domain of epithelial cell adhesion 
molecule correlates with poor patient outcome in primary colorectal 
adenocarcinoma. Curr Oncol. 2016;23:171-8.
15. Bologna-Molina R, González-González R, Mosqueda-Taylor A, 
Molina-Frechero N, Damián-Matsumura P, Dominguez-Malagón H. 
Expression of Syndecan-1 in Papillary Carcinoma of the Thyroid 
with Extracapsular Invasion . Arch Med Res. 2010;401:33-7.
16. Trautman MS, Kimelman J, Bernfield M. Developmental expres-
sion of syndecan, an integral membrane proteoglycan, correlates 
with cell differentiation. Develop. 1991;111:213-20.
17. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL, 
Bernfield M. Immunocytochemistry of cell surface heparan sulfate 
proteoglycan in mouse tissues. A light and electron microscopic 
study. J Histochem Cytochem. 1987;35:1079-88.
18. Vainio S, Jalkanen M, Vaahtokari A, Sahlberg C, Mali M, Bern-
field M, et al. Expression of syndecan gene is induced early, is tran-
sient, and correlates with changes in mesenchymal cell proliferation 
during tooth organogenesis. Dev Biol. 1991;147:322-33.
19. Elenius K, Salmivirta M, Inki P, Mali M, Jalkanen M. Binding 
of human syndecan to extracellular matrix proteins. J Biol Chem. 
1990;265:17837-43.
20. Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman 
T, et al. Identification of a Wnt/Dvl/beta-catenin PITX2 pathway 
mediating cell-type-specific proliferation during development. Cell. 
2002;111:673-85.
21. Wang Y, Li L, Zheng Y, Yuan G, Yang G, He F, et al. BMP activ-
ity is required for tooth development from the lamina to bud stage. J 
Dent Res. 2012;91:690-5. 
22. Mucchielli ML, Mitsiadis TA, Raffo S, Brunet JF, Proust JP, 
Goridis C. Mouse Otlx2/RIEG expression in the odontogenic epi-
thelium precedes tooth initiation and requires mesenchyme-derived 
signals for its maintenance. Dev Biol. 1997;189:275-84.
23. Gordon N, Newton RW. Glucose transporter type1 (GLUT-1) de-
ficiency. Brain Dev. 2003;25:477-80.
24. Sánchez-Romero C, Bologna-Molina R, Mosqueda-Taylor A, Al-
meida OP. Immunohistochemical Expression of GLUT-1 and HIF-1α 
in Tooth Germ, Ameloblastoma, and Ameloblastic Carcinoma. Int J 
Surg Pathol. 2016;24:410-8.
25. Martínez-Mata G, Mosqueda-Taylor A, Carlos-Bregni R, de 
Almeida OP, Contreras-Vidaurre E, Vargas PA, et al. Odontogenic 
myxoma: clinico-pathological, immunohistochemical and ultrastruc-
tural findings of a multicentric series. Oral Oncol. 2008;44:601-7.
26. Newlaczyl AU, Yu LG. Galectin-3–a jack-of-all-trades in cancer. 
Cancer Lett. 2011;313:123-8.
27. Tuğçe C. Immunhistochemical expression of galectin-3 in cancer: 
a review of the literature. Türk Patoloji Dergisi. 2012:28:1-10.
28. Nakahara S, Raz A. Regulation of cancer-related gene expres-
sion by galectin-3 and the molecular mechanism of its nuclear import 
pathway. Cancer Met Rev. 2007;26:605-10.
29. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging 
role in normal adult tissues. Mol Cancer Ther. 2006;5:1087-98.
30. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 
1999;17:2941-53.
31. Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic pro-
teins and matrix metalloproteinases in odontogenic myxomas. J Oral 
Maxillofac Surg. 2003;61:1463-6.
32. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz 
M. Immunohistochemical study on survivin in sinonasal tumors and 
its relationship with the immunoexpression of Ki67 and Bcl-2. Folia 
Histochem Cytobiol. 2013;51:225-31.
33. Basu A, Haldar S. The relationship between Bcl-2, Bax and p53: 
consequences for cell cycle progression and cell death. Mol Hum Re-
prod. 1998;4:1099-109.
34. Del Carmen González-Galván M, Aguirre-Urizar JM, Bologna-
Molina R, Farfán-Morales JE, Gainza-Cirauqui ML, Marichalar-
Mendia X, et al. Assessment of CD-105 as an Angiogenic Modulator 
in Odontogenic Myxomas and Dental Follicles. Int J Surg Pathol. 
2016;24:315-9.
35. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, 
Delia D, et al. Expression of the CD34 gene in vascular endothelial 
cells. Blood. 1990;75:2417-26.
36. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Con-
cise review: evidence for CD34 as a common marker for diverse pro-
genitors. Stem Cells. 2014;32:1380-9.
37. Brown J, Greaves MF, Molgaard HV. The gene encoding the stem 
cell antigen, CD34, is conserved in mouse and expressed in haemo-
poietic progenitor cell lines, brain, and embryonic fibroblasts. Int 
Immunol. 1991;3:175-84.
38. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J 
Cell Sci. 2008;121:3683-92.
39. Lin CS, Ning H, Lin G. Is CD34 truly a negative marker for mes-
enchymal stromal cells? Cytotherapy. 2012;14:1159-63.
40. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-
matrix interactions in axon regeneration, apoptosis, adhesion, migra-
tion, cancer, and fibrosis. FASEB J. 2006;20:1045-54.
41. Silva FP, Dias A, Coelho CA, Guerra EN, Marques AE, Decur-
cio DA, et. al. Expression of CD90 and P75NTR stem cell markers 
in ameloblastomas: a possible role in their biological behavior. Braz 
Oral Res. 2016;30:109.
42. Schwab W, Harada H, Goetz W, Nowicki M, Witt M, Kasper M, 
et al. Immunocytochemical and biochemical detection of EMMPRIN 
in the rat tooth germ: Differentiation-dependent co-expression with 
MMPs and co-localization with caveolin-1 in membrane rafts of den-
tal epithelial cells. Histochem Cell Biol. 2007;128:195-203.
43. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transforma-
tion, cancer and metastasis. Am J Phisiol. 2005;288:494-506.
44. Yang SF, Yang JY, Huang CH, Wang SN, Lu CP, Tsai CJ, et al. 
Increased caveolin-1 expression associated with prolonged overall 
survival rate in hepatocellular carcinoma. Pathol. 2010;42:438-45.
Med Oral Patol Oral Cir Bucal. 2017 May 1;22 (3):e314-23.                                                                                                                                                                    Primordial odontogenic tumor
e323
45. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, et al. 
Loss of TGF-ß signaling and PTEN promotes head and neck squa-
mous cell carcinoma through cellular senescence evasion and can-
cer-related inflammation. Oncogene 2012;31:3322-32.
46. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, 
Kwei KA. Identification of recurrent SMO and BRAF mutations in 
ameloblastomas. Nat Genet. 2014;46:722-5.
47. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim 
MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblas-
toma. Clin Cancer Res. 2014;20:5517-26.
48. Diniz MG, Gomes CC, Guimarães BV, Castro WH, Lacerda JC, 
Cardoso SV, et al. Assessment of BRAFV600E and SMOF412E muta-
tions in epithelial odontogenic tumours. Tumour Biol. 2015;36:5649-
53.
Conflict of Interest
The authors have declared that no conflict of interest exist.
